Ac-225-PSMA-617
225Ac-PSMA-617 is the next generation of prostate cancer treatment following [...]
Lu-177-iPSMA
177Lu-iPSMA is the therapeutic analogue of 99mTc-iPSMA developed at [...]
Th-227-Pelgifatamab
227Th-Pelgifatamab(227Th-PSMA-TTC, 227Th-BAY2315497) is a Thorium-227 labelled PSMA-targeted full IgG antibody [...]
I-131-RPS-001
131I-RPS-001 (131I-MIP-1095) is a small radiolabeled molecule, a glutamate-urea-lysine analogue, [...]
Lu-177-CTT-1403
177Lu-CTT1403 is the therapeutic analogue of 18F-CTT1057, a phosphoramide based [...]
Lu-177-EB-PSMA-617
177Lu-EB-PSMA-617 is a PSMA-617 analogue developed in China as an [...]
Lu-177-PSMA-R2
177Lu-PSMA-R2 was developed as patent protected equivalent of 177Lu-PSMA-617. This [...]
Ac-225-Rosopatamab
225Ac-Rosopatamab (225Ac-CONV-01-α) is an alpha-radiolabeled monoclonal antibody targeting PSMA [...]
Lu-177-PNT2002
177Lu-PNT2002 (formerly 177Lu-PSMA-I&T) is a peptide developed by the [...]
Cu-67-SAR-bisPSMA
67Cu-SARbisPSMA is a new PSMA targeting drug labeled with [...]